TPST-1120

PreclinicalSmall molecule

Roche

TPST-1120 is one of 50 small molecule programs targeting Liver Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

Advanced Liver CancersRecruiting

Liver CancerPhase 1/Phase 2

Active, not recruiting

Advanced Liver CancersPreclinical

Recruiting

Competition

Competitive Landscape

261 competitors in Liver Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

35 2

Opdivo

Bristol-Myers Squibb

Phase 3

15 3

Eloxatin

Teva

Phase 3

8 4

Adriamycin

Pfizer

Phase 3

7 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

14 6

Imjudo

AstraZeneca

Phase 3

3 7

Gemzar

Johnson & Johnson

Phase 3

2 8

Adriamycin

GGynecologic Oncology Group

Phase 3

11 9

Megace

Bristol-Myers Squibb

Phase 3

1 10

Bayer Aspirin

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Advanced Liver Cancers

NCT04524871

Q3 2030

Phase 3Not yet recruiting

Systemic Therapy

NCT06680258

Clinical

Trials by Indication[1]

Systemic Therapy1 trial

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Not yet recruiting·TTempest Therapeutics·Phase 3·NCT06680258·740 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Recruiting· Roche logo

Roche·Preclinical·NCT04524871·518 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TPST-1120. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TPST-1120 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TPST-1120. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Roche

TPST-1120

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2030

Trials by Indication[1]

Systemic Therapy1 trial

Advanced Liver Cancers1 trial

References

Drug Info

Quick Facts

Related News